CDT Equity Inc. Announces Reverse Stock Split
Rhea-AI Summary
CDT Equity (Nasdaq: CDT) has approved a 1-for-10 reverse stock split of its common stock to support continued compliance with Nasdaq’s bid-price rule. The split becomes effective on July 17, 2026 at 5:00 p.m. ET, with split-adjusted trading on Nasdaq beginning July 20, 2026 under the existing ticker CDT and a new CUSIP, 20678X601.
At the effective time, every 10 issued and outstanding shares will be combined into one share, with par value unchanged at $0.0001. Outstanding shares are expected to be reduced to approximately 631,077. Equity awards, convertible securities, warrants and plan reserves will be proportionally adjusted. No fractional shares will be issued; affected holders will receive cash instead. Continental Stock Transfer & Trust will act as exchange agent, and most shareholders will not need to take action.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- 1-for-10 reverse split supports Nasdaq bid-price rule compliance
- Outstanding common shares reduced to approximately 631,077 post-split
- Par value per share remains at $0.0001
- Equity awards and convertible securities adjusted proportionally to maintain economics
Negative
- Stockholders entitled to fractional shares will receive cash instead of fractional shares
- Reverse stock split consolidates every 10 shares into one share
- New CUSIP and share count change may require administrative updates for some holders
Market reaction: CDT -12.31% on 1-for-10 reverse stock split
Following this news, CDT has declined 12.31%, reflecting a significant negative market reaction. The stock is currently trading at $0.31. This price movement has removed approximately $239K from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Stock split Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 25 | Reverse stock split | Negative | -12.0% | Announced 1-for-25 reverse split with trading on split-adjusted basis on Nasdaq. |
| Oct 09 | Reverse stock split | Negative | -11.9% | Approved 1-for-8 reverse split, reducing outstanding shares and changing CUSIP. |
| May 16 | Reverse stock split | Negative | -4.4% | Declared 1-for-15 reverse split to reduce share count and adjust awards. |
| Jan 23 | Reverse stock split | Negative | -20.0% | Announced 1-for-100 reverse split to address Nasdaq minimum bid requirement. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
CDT’s prior reverse stock split announcements have consistently been followed by negative one-day price reactions.
Key Terms
reverse stock split financial
nasdaq bid-price rule regulatory
par value financial
cusip technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-10 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.
The reverse stock split will become effective on July 17, 2026, at 5:00 pm, Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) at market open under the existing ticker symbol, “CDT” on July 20, 2026, the date which has been approved by Nasdaq for the effectiveness of such split.
As of the Effective Time, every 10 shares of the Company’s issued and outstanding common stock will be combined into one share of common stock. The par value per share of the Company’s common stock will remain unchanged at
The Company’s common stock will continue to trade on Nasdaq under the symbol “CDT” following the reverse stock split, with a new CUSIP number of 20678X601. After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced to approximately 631,077. No fractional shares will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to a fractional share will receive a proportional cash payment.
The Company’s transfer agent, Continental Stock Transfer & Trust Co., will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-reverse stock split shares of common stock electronically in book-entry form are not required to take any action to receive post-reverse stock split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.
About CDT Equity Inc.
CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.
Investors
CDT Equity Inc.
Info@cdtequity.com
